Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger

Kummer, Nicole; Feinn, Richard; Griffin, Daniel; Nulsen, John; Benadiva, Claudio; Engmann, Lawrence

doi:10.1093/humrep/des361

Cited by 81 publications

(98 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another important aspect of agonist-triggered cycles is the incidence of empty follicle syndrome (EFS). The incidence of EFS has been reported as 0.6%-3.5% in GnRHa trigger cycles, which is similar to that reported (0.1%-3.1%) after an hCG trigger (12,19,(25)(26)(27)(28)(29). Therefore, EFS is not an inherent and exclusive problem to the GnRHa trigger (25) but could be related to human error, abnormalities in the in vivo biological activity of some batches of commercially available GnRHa, hypothalamic dysfunction, or GnRH receptor mutations (23,26,(28)(29)(30).…”

Section: Discussionsupporting

confidence: 86%

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Gülekli¹,

Göde²,

Sertkaya³

et al. 2015

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Objective:To investigate the efficacy of low-dose gonadotropin-releasing hormone (GnRH) agonist for final oocyte maturation in females undergoing assisted reproductive treatment (ART) cycles. Material and Methods:Nine females undergoing ovarian stimulation in a GnRH antagonist protocol who received triptorelin 0.1 mg to trigger final oocyte maturation were included. Treatment outcomes of these patients were compared with those of controls, matched for age and oocyte number (n=14), who received 0.2 mg triptorelin at the same time. The luteal phase was supported with vaginal micronized progesterone and oral estradiol hemihydrate 2 mg twice daily. Results:The mean (±) numbers of retrieved, metaphase II, and fertilized oocytes were 15.66±7.82, 14±7.28, and 10.11±5.86, respectively.The implantation and clinical pregnancy rates were 46.1% and 71.4%, respectively. Of the pregnancies, 2 were live births, 1 was a preterm birth (twins), 2 are on-going, and 2 ended as miscarriages. No case of OHSS was encountered. On comparison of the results of these patients (fresh cycles; n=7) with those of matched controls, there were no significant differences in terms of retrieved mature oocytes, implantation rates, or clinical pregnancy rates (p>0.05). Conclusion:These findings suggest that low-dose GnRH agonist triggering has similar efficacy as standard doses in terms of retrieved mature oocytes and clinical pregnancy rates in in vitro fertilization cycles. (J Turk Ger Gynecol Assoc 2015; 16: 35-40) Keywords: Agonist trigger, triptorelin, oocyte maturation, oocyte retrieval, pregnancy rate Received: 21 June, 2014 Accepted: 05 December, 2014 Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series AbstractOriginal Investigation

show abstract

Section: Discussionsupporting

confidence: 86%

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Gülekli¹,

Göde²,

Sertkaya³

et al. 2015

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

show abstract

“…Borderline hypothalamic -pituitary dysfunction may be an etiology for EFS after GnRH agonist trigger. 11,14 Management of patients with EFS is a challenge for clinicians. Unfortunately no single treatment is known to be universally effective.…”

Section: Discussionmentioning

confidence: 99%

Empty follicle syndrome after GnRH agonist trigger, rescued with HCG in a donor oocyte with successful pregnancy outcome: a case report

Mahapatro

Shankar

Varma

2016

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

“…[18] Gonadotropin salgılatıcı hormon (GnRH) antagonisti sikluslarında endojen LH salınımı için GnRH agonisti kullanıldığında boş folikül sendromuyla karşı-laşma oranı %1.4 oranında bildirilmektedir. [19] Bizim ça-lışmamızda tüm final oosit maturasyonu rekombinant hCG ile yapıldı ve boş folikül sendromu oranımız %1.4 idi. Castillo ve ark.…”

Section: Discussionunclassified

Our Reasons for Cancellation During Intracytoplasmic Sperm Injection Cycles

Özkan¹,

Ekinci²,

Timurkan³

et al. 2014

J Kartal TR

View full text Add to dashboard Cite

ÖzetAmaç: Yardımcı üreme teknikleri (YÜT) ile tedaviye alınan çiftlerde tedavinin yarıda bırakılması nadir görülen bir durum değildir. Stimülasyonun yarıda bırakılması veya embriyo transferine gidilememesi birçok farklı nedene bağlı olabilir. Bu yazıda Tüp Bebek Ünitemizde iptale giden olgularımızın özelliklerini irdeledik. Gereç ve Yöntem:Hastanemiz Tüp Bebek Ünitesi'nde Mayıs 2010-Ekim 2012 tarihleri arasında tedaviye alınan 554 çiftin kontrollü overyan hiperstimülasyon-intrasitoplazmik sperm injeksiyonu (KOH-ICSI) tedavilerinin geriye dönük analizi yapıldı.

show abstract

Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger

Abstract: n/a.

Cited by 81 publications

References 46 publications

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series

Empty follicle syndrome after GnRH agonist trigger, rescued with HCG in a donor oocyte with successful pregnancy outcome: a case report

Our Reasons for Cancellation During Intracytoplasmic Sperm Injection Cycles

Contact Info

Product

Resources

About